TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy
Brief Summary: To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.


Options:
A: Arm Label: Burst SCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10) | Intervention Type: DEVICE; Name: Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10); Assigned to Arm(s): Burst SCS, Sham
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pregabalin 300 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Pregabalin 600 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 300 mg/day | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 600 mg/day
C: Arm Label: Spinal Cord Stimulation (SCS); Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal Cord Stimulation | Arm Label: Conventional Medical Management (CMM); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Medical Management | Intervention Type: DEVICE; Name: Spinal Cord Stimulation; Assigned to Arm(s): Spinal Cord Stimulation (SCS) | Intervention Type: OTHER; Name: Conventional Medical Management; Assigned to Arm(s): Conventional Medical Management (CMM)
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy
Brief Summary: To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: pregabalin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (unspecified) | Intervention Type: DRUG; Name: Comparator: pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Comparator: Placebo (unspecified); Assigned to Arm(s): B
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pregabalin 300 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Pregabalin 600 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 300 mg/day | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 600 mg/day
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.


Options:
A: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo
B: Arm Label: VI-0521 Top; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: VI-0521 Mid; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: VI-0521 | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Top | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Mid | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): Placebo
C: Arm Label: Lorcaserin 10 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg once daily (QD) | Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg twice a day (BID) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Lorcaserin 10 mg once daily (QD); Assigned to Arm(s): Lorcaserin 10 mg QD | Intervention Type: DRUG; Name: Lorcaserin 10 mg twice a day (BID); Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period
Brief Summary: The purpose of this study is to determine whether Asacol® 2.4 g/day (400 mg Mesalamine) is safe and effective in the treatment of diverticulitis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Dietary Advice, Drug: Antibiotic for Diverticulitis | Arm Label: Mesalamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine, Other: Dietary Advice, Drug: Antibiotic for Diverticulitis | Arm Label: Mesalamine & Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Probiotic, Other: Dietary Advice, Drug: Antibiotic for Diverticulitis | Intervention Type: DRUG; Name: Mesalamine; Assigned to Arm(s): Mesalamine | Intervention Type: DRUG; Name: Probiotic; Assigned to Arm(s): Mesalamine & Probiotic | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Dietary Advice; Assigned to Arm(s): Mesalamine, Mesalamine & Probiotic, Placebo | Intervention Type: DRUG; Name: Antibiotic for Diverticulitis; Assigned to Arm(s): Mesalamine, Mesalamine & Probiotic, Placebo
B: Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine 800 mg | Arm Label: Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactobacillus casei | Arm Label: Mesalazine plus Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine plus Lactobacillus casei | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalazine placebo plus Lactobacillus casei placebo | Intervention Type: DRUG; Name: Mesalazine plus Lactobacillus casei; Assigned to Arm(s): Mesalazine plus Lactobacillus casei | Intervention Type: DRUG; Name: Mesalazine placebo plus Lactobacillus casei placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mesalazine 800 mg; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Lactobacillus casei; Assigned to Arm(s): Lactobacillus casei
C: Arm Label: Antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antibiotic | Arm Label: No antibiotic; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antibiotic; Assigned to Arm(s): Antibiotic
D: Arm Label: SPD476 (1.2 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (1.2g) | Arm Label: SPD476 (2.4 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (2.4 g) | Arm Label: SPD476 (4.8 g); Type: EXPERIMENTAL; Interventions: Drug: SPD476 (4.8 g) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SPD476 (1.2g); Assigned to Arm(s): SPD476 (1.2 g) | Intervention Type: DRUG; Name: SPD476 (2.4 g); Assigned to Arm(s): SPD476 (2.4 g) | Intervention Type: DRUG; Name: SPD476 (4.8 g); Assigned to Arm(s): SPD476 (4.8 g) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial
Brief Summary: A major goal in public health is to find effective, feasible and simple programs for overweight prevention among children. This controlled intervention study evaluates a simple environmental and behavioral modification for its efficacy in preventing overweight of children in the school setting. The intervention strategy focuses solely on the promotion of drinking tap water. The study was conducted in 32 elementary schools including about 3000 children in two German cities over 1 school year.


Options:
A: Arm Label: Healthy Lifestyle (Active Intervention); Type: OTHER; Interventions: Behavioral: Multiple behavior interventions | Arm Label: Healthy Drinks (Active Intervention); Type: OTHER; Interventions: Behavioral: Single behavior intervention | Arm Label: Social and Leadership Skills (Control Intervention); Type: OTHER; Interventions: Behavioral: Control Intervention unrelated to weight | Intervention Type: BEHAVIORAL; Name: Single behavior intervention; Assigned to Arm(s): Healthy Drinks (Active Intervention) | Intervention Type: BEHAVIORAL; Name: Multiple behavior interventions; Assigned to Arm(s): Healthy Lifestyle (Active Intervention) | Intervention Type: BEHAVIORAL; Name: Control Intervention unrelated to weight; Assigned to Arm(s): Social and Leadership Skills (Control Intervention)
B: Arm Label: H2GO! intervention; Type: EXPERIMENTAL; Interventions: Behavioral: H2GO! | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: H2GO!; Assigned to Arm(s): H2GO! intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sugar-sweetened beverage consumption | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sugar-sweetened beverage consumption; Assigned to Arm(s): 1
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: environmental and behavioral change | Intervention Type: BEHAVIORAL; Name: environmental and behavioral change; Assigned to Arm(s): Intervention group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial
Brief Summary: A major goal in public health is to find effective, feasible and simple programs for overweight prevention among children. This controlled intervention study evaluates a simple environmental and behavioral modification for its efficacy in preventing overweight of children in the school setting. The intervention strategy focuses solely on the promotion of drinking tap water. The study was conducted in 32 elementary schools including about 3000 children in two German cities over 1 school year.


Options:
A: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: environmental and behavioral change | Intervention Type: BEHAVIORAL; Name: environmental and behavioral change; Assigned to Arm(s): Intervention group
C: Arm Label: SCORES; Type: EXPERIMENTAL; Interventions: Behavioral: America SCORES, Bay Area | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: America SCORES, Bay Area; Assigned to Arm(s): SCORES
D: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Brief Summary: * Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN
* Investigation of differences between the treatments regarding the number of patients loosing more than 15 ml/min of GFR.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Placebo | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren, Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): I, II
B: Arm Label: sparsentan; Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Arm Label: irbesartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: irbesartan | Arm Label: dapagliflozin + sparsentan (Sub study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan, Drug: Dapagliflozin | Arm Label: sparsentan (Sub Study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Intervention Type: DRUG; Name: sparsentan; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study), sparsentan, sparsentan (Sub Study) | Intervention Type: DRUG; Name: irbesartan; Assigned to Arm(s): irbesartan | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study)
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive therapy with: ACE-inhibitor / ARB / Statin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive and immunosuppressive therapy | Intervention Type: DRUG; Name: supportive therapy with: ACE-inhibitor / ARB / Statin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: supportive and immunosuppressive therapy; Assigned to Arm(s): B
D: Arm Label: Control Group; Type: EXPERIMENTAL; Interventions: Drug: Immunosuppressants, Other: Optimized Supportive Care, Other: Yi-Qi-Qing-Jie herbal compound placebo | Arm Label: YQF Group; Type: EXPERIMENTAL; Interventions: Drug: The Yi-Qi-Qing-Jie herbal compound, Drug: Immunosuppressants, Other: Optimized Supportive Care | Intervention Type: DRUG; Name: The Yi-Qi-Qing-Jie herbal compound; Assigned to Arm(s): YQF Group | Intervention Type: DRUG; Name: Immunosuppressants; Assigned to Arm(s): Control Group, YQF Group | Intervention Type: OTHER; Name: Optimized Supportive Care; Assigned to Arm(s): Control Group, YQF Group | Intervention Type: OTHER; Name: Yi-Qi-Qing-Jie herbal compound placebo; Assigned to Arm(s): Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Brief Summary: * Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN
* Investigation of differences between the treatments regarding the number of patients loosing more than 15 ml/min of GFR.


Options:
A: Arm Label: NEFECON 8 mg/day; Type: EXPERIMENTAL; Interventions: Drug: NEFECON | Arm Label: NEFECON 16 mg/day; Type: EXPERIMENTAL; Interventions: Drug: NEFECON | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: NEFECON; Assigned to Arm(s): NEFECON 16 mg/day, NEFECON 8 mg/day | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Tacrolimus group; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: oral methylprednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): oral methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive therapy with: ACE-inhibitor / ARB / Statin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive and immunosuppressive therapy | Intervention Type: DRUG; Name: supportive therapy with: ACE-inhibitor / ARB / Statin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: supportive and immunosuppressive therapy; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Continuous Positive Airway Pressure on Short Term Inhospital Prognosis for Acute Pulmonary Edema
Brief Summary: The investigators hypothesise that CPAP + pharmaceutical treatment, compared to pharmaceutical treatment alone, improves the respiratory and hemodynamic status of the patients before H2 after the inclusion time and decreases the rate of death and tracheal intubation during the first 48 hours.


Options:
A: Arm Label: CPAP; Type: EXPERIMENTAL; Interventions: Procedure: CPAP | Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard treatment | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP | Intervention Type: DRUG; Name: standard treatment; Assigned to Arm(s): standard medical therapy
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: usual care of acute pulmonary oedema | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Continuous Positive Airway Pressure (CPAP) | Intervention Type: PROCEDURE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: usual care of acute pulmonary oedema; Assigned to Arm(s): A
C: Intervention Type: DEVICE; Name: CPAP and Non Invasive Ventilation; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Total face mask (interface for NPPV) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Comfort full or RT040 oronasal mask (interface for NPPV) | Intervention Type: DEVICE; Name: Total face mask (interface for NPPV); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Comfort full or RT040 oronasal mask (interface for NPPV); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Intervention for DM Guideline Implementation
Brief Summary: This is a multi-site open label randomized controlled study of patients with type 2 diabetes undergoing pharmacist-led group medical visits that include education by a multi-disciplinary personnel, behavioral modification and pharmacotherapy case management vs. usual care


Options:
A: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing
B: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Cognitive Behavioral Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Office System Redesign Intervention | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Office System Redesign Intervention; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Physician-pharmacist collaborative intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physician-pharmacist collaborative intervention; Assigned to Arm(s): 1
D: Arm Label: Pharmacist-led Group Visits; Type: EXPERIMENTAL; Interventions: Other: Algorithm driven medication titration, Behavioral: Monitoring, Behavioral: Group support, Behavioral: Self efficacy | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Algorithm driven medication titration; Assigned to Arm(s): Pharmacist-led Group Visits | Intervention Type: BEHAVIORAL; Name: Monitoring; Assigned to Arm(s): Pharmacist-led Group Visits | Intervention Type: BEHAVIORAL; Name: Group support; Assigned to Arm(s): Pharmacist-led Group Visits | Intervention Type: BEHAVIORAL; Name: Self efficacy; Assigned to Arm(s): Pharmacist-led Group Visits

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux
Brief Summary: The study prospectively compares two treatment algorithms for newly diagnosed Crohn's disease: one 'aggressive' treatment with early introduction of immunomodulators and biologicals and one 'standard treatment' with corticosteroids and only later introduction of immunosuppressives and biologicals if disease activity requires that.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LDP-02 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LDP-02 | Intervention Type: DRUG; Name: LDP-02; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A